GreenPrints Institutional repository of De La Salle Medical and Health Sciences Institut
Not a member yet
6526 research outputs found
Sort by
Meditation
No full text1819-RPA-097https://greenprints.dlshsi.edu.ph/collections_3d/1037/thumbnail.jp
Holy Night Nativity 3
No full text2122-RPA-317https://greenprints.dlshsi.edu.ph/collections_3d/1074/thumbnail.jp
Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group
No full textBackground. Dengue is an increasing threat to global health. This exploratory analysis evaluated the immunogenicity, safety, and vaccine efficacy (VE) of a live-attenuated tetravalent dengue vaccine (TAK-003) in participants enrolled in the phase 3 DEN-301 trial (NCT02747927), stratified by baseline age (4–5 years, 6–11 years, or 12–16 years). Methods. Participants were randomized 2:1 to receive 2 doses of TAK-003, administered 3 months apart, or placebo. Dengue serostatus was evaluated at enrolment. VE against virologically confirmed dengue (VCD) and hospitalized VCD; immunogenicity (geometric mean titers [GMTs]); and safety were evaluated per age group through ∼4 years postvaccination. Results. VE against VCD across serotypes was 43.5% (95% confidence interval [CI]: 25.3%, 57.3%) for 4–5 year-olds; 63.5% (95% CI: 56.9%, 69.1%) for 6–11 year-olds, and 67.7% (95% CI: 57.8%, 75.2%) for 12–16 year-olds. VE against hospitalized VCD was 63.8% (95% CI: 21.1%, 83.4%), 85.1% (95% CI: 77.1%, 90.3%), and 89.7% (95% CI: 77.9%, 95.2%), for the 3 age groups, respectively. GMTs remained elevated against all 4 serotypes for ∼4 years postvaccination, with no evident differences across age groups. No clear differences in safety by age were identified. Conclusions. This exploratory analysis shows TAK-003 was efficacious in dengue prevention across age groups in children and adolescents 4–16 years of age living in dengue endemic areas. Relatively lower VE in 4–5 year-olds was potentially confounded by causative serotype distribution, small sample size, and VE by serotype, and should be considered in benefit-risk evaluations in this age group
Artwork 018: Cups Cafe
No full textFor the price: Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/painting/1017/thumbnail.jp
Artwork 005: Bonzai
No full textFor the price: Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/sculpture/1004/thumbnail.jp
Artwork 004: Cockatiel
No full textFor the price: Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/sculpture/1003/thumbnail.jp
Meeting proceedings: International Society for Fertility Preservation Tokyo, 15–17 November, 2024
No full textThe 8 th International Congress of the ISFP was held in Tokyo, Japan, from November 15 to 17, 2024. The theme of this year’s Congress was “Rethinking Personalized Fertility Preservation and Cancer Survivors-Opening a New Frontier”. The congress featured special lectures, keynote addresses, and 25 sessions—including a dedicated session on nursing and oral presentations by young doctors and researchers—making it one of the largest and most comprehensive events in the ISFP’s history. Additionally, the program incorporated sessions featuring the Japanese, Korean, and Chinese Societies for Fertility Preservation, providing a convenient platform for international participants from across the globe to showcase their work and discuss the unique characteristics and challenges of these areas within Asia. Participants also had the opportunity to attend workshops on ovarian tissue cryopreservation and oocyte cryopreservation, conducted by leaders in their respective fields exploring the latest technological and clinical advances and translational prospects for the future